Suidan Marc sold (to issuer) $180K of BLZE

Boundless Bio (BOLD) and Backblaze (BLZE) stocks surged 85% and 43% respectively, while Quantinuum (QNT) gained 13%. BOLD rose after a merger deal with Serapha Bio, including $230M in funding. BLZE reached a 2-year high after a $335M AI cloud deal. QNT hit a record high following a White House quantum tech development order.

Backblaze (BLZE) priced a $175M upsized convertible notes offering, up from $150M, with an option for $26.25M more. Notes mature in 2031, convertible at $21.94/share, a 30% premium. Proceeds, ~$167.2M, will fund corporate purposes and capital expenditures.

Backblaze proposed a $150 million offering of convertible senior notes. The company's stock is currently trading at $19.20, with a 5-day change of -0.98% and a year-to-date change of +312.02%.

Backblaze (BLZE) stock fell 8.3% in after-hours trading to $17.60 after announcing a $150M convertible note offering, with a 13-day over-allotment option for $22.5M more. The company's stock had risen over 60% in two weeks prior. The broader market was relatively flat, indicating the decline was company-specific. The notes, due 2031, may dilute existing shares. BofA Securities is leading the deal.

Backblaze (BLZE) plans to offer $150M in convertible notes due 2031, with an option for $22.5M more. Proceeds will be used for capped call transactions, corporate purposes, and capital expenditures. BofA Securities is the lead bookrunner. The notes are for qualified institutional buyers under Rule 144A.

Backblaze Inc (BLZE) shares fell 6.7% after announcing a $150M convertible notes offering due 2031. The company plans to use proceeds for capped call transactions, corporate purposes, and capital expenditures. BofA Securities is leading the offering. The notes may convert into cash, stock, or a combination, with terms to be determined.